Mary Beegle, DO
Psychiatry · Sedalia, MONPI 1659488419
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $949 and has fallen 81.4% since, to $177 in 2025.
Across 238 payments — averaging $12.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$642
- Supernus Pharmaceuticals, Inc.$444
- AbbVie$346
- Neurocrine Biosciences, Inc.$324
- Teva Pharmaceuticals USA, Inc.$233
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$166
- plus $819 from 13 others
What the payments were for
- Food & beverage$2,89097%
- Education$843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 59 | $642 |
| Supernus Pharmaceuticals, Inc. | 63 | $444 |
| AbbVie(2 entities) | 14 | $346 |
| Neurocrine Biosciences, Inc. | 26 | $324 |
| Teva Pharmaceuticals USA, Inc. | 19 | $233 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $166 |
| Otsuka America Pharmaceutical, Inc. | 10 | $165 |
| Merck | 8 | $146 |
| Eisai Inc. | 7 | $143 |
| Johnson & Johnson | 7 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $55 |
| Indivior Inc. | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Alkermes, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,973 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $275,552 |
| VraylarCariprazine Hcl | 49 | $90,195 |
| TrintellixVortioxetine Hydrobromide | 64 | $44,390 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,234 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $24,538 |
| FetzimaLevomilnacipran Hcl | 38 | $23,569 |
| Risperidone ErRisperidone Microspheres | 13 | $20,490 |
| VyvanseLisdexamfetamine Dimesylate | 42 | $19,645 |
| BelsomraSuvorexant | 39 | $17,050 |
| Lurasidone Hcl | 33 | $16,708 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $12,058 |
| DayvigoLemborexant | 35 | $11,756 |
| Clomipramine Hcl | 65 | $11,370 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 212 | $6,454 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 102 | $5,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $324 | $275,55229 claims |
| AbbVieVraylar, Fetzima | $346 | $113,76587 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $55 | $64,035106 claims |
| Johnson & JohnsonInvega Sustenna | $122 | $36,23411 claims |
| MerckBelsomra | $146 | $17,05039 claims |
| Axsome Therapeutics, Inc.Auvelity | $20 | $12,05819 claims |
| Eisai Inc.Dayvigo | $143 | $11,75635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Sedalia
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.